MRNA Jumps 14.9%, NVAX Up 12.7% as Healthcare Stocks Ride EPS Revisions
Moderna (MRNA) surged 14.9% to $226.30 after its forward EPS growth estimate was revised to 42.9%, while Novavax (NVAX) rose 12.7% to $12.64 on a 20-percentage-point EPS revision for next year. Other notable gainers included AGBK (+10.4%), WQEY (+10.2%), and VRA (+9.5%), driven by upward earnings estimate revisions across sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| MRNA | Healthcare | 2026-10-08 | N/A | +14.9% |
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +12.7% |
| AGBK | Financial | 2026-10-08 | N/A | +10.4% |
| WQEY | Technology | 2026-10-09 | +12.4pp | +10.2% |
| VRA | Consumer Cyclical | 2026-10-09 | +63.6pp | +9.5% |
Why did MRNA stock jump in October 2026?
MRNA jumped 14.9% (from $197.00 to $226.30) after analysts raised its forward EPS growth estimate to 42.9% on October 8.
The revision, flagged by our earnings screener, reflects improving expectations for Moderna's mRNA pipeline and cost discipline. Supporting the move, the company announced on October 13 that it will report Q3 2026 results on November 6, heightening investor anticipation of a positive earnings surprise. Sector-wide attention on healthcare stocks also provided a tailwind as the market rotated toward defensive names amid tech weakness.
MRNA EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: MRNA
Why did MRNA stock jump?
MRNA jumped 14.9% after its forward EPS growth estimate was revised upward to 42.9% on October 8, with additional momentum from the announcement of its Q3 earnings date.
Is MRNA a buy after the rally?
The stock's gain reflects improved earnings expectations and upcoming Q3 results, but investors should weigh the 14.9% rally against potential volatility around the November 6 earnings report.
What is Moderna's EPS growth estimate?
Analysts currently project Moderna's EPS to grow 42.9% next year, up from prior estimates, driven by pipeline advancements and cost management.
Why did NVAX stock jump in October 2026?
NVAX jumped 12.7% (from $11.22 to $12.64) after its next-year EPS growth estimate was revised from 77.3% to 97.3% on October 7.
The 20-percentage-point upgrade, captured by our screener, signals growing analyst confidence in Novavax's earnings trajectory. With no company-specific news, the move likely reflects sector-wide momentum in healthcare stocks and positioning ahead of earnings season. The magnitude of the revision underscores improving profitability prospects, even as the stock remains a high-risk, high-reward play.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock surge?
NVAX surged 12.7% following a 20-percentage-point upward revision to its next-year EPS growth estimate, from 77.3% to 97.3%, on October 7.
Is NVAX a buy after the rally?
The strong EPS revision suggests improving fundamentals, but the stock's 12.7% jump may have priced in much of the near-term optimism; consider valuation and volatility.
What caused NVAX's EPS estimate revision?
No specific news was found, but the revision likely stems from analyst adjustments to Novavax's cost structure and revenue outlook for 2027.
Why did AGBK stock jump in October 2026?
AGBK jumped 10.4% (from $6.51 to $7.19) after analysts set its forward EPS growth estimate at 44.5% on October 8.
The revision, identified by our screener, highlights expectations for strong earnings growth in the financial sector. With no company-specific news, the gain may reflect broader optimism around financial stocks as interest rates stabilize. The move suggests the market is rewarding companies with robust earnings outlooks amid a mixed economic backdrop.
AGBK EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: AGBK
Why did AGBK stock jump?
AGBK jumped 10.4% after its forward EPS growth estimate was established at 44.5% on October 8, signaling strong expected earnings growth.
What is AGBK's EPS growth estimate?
AGBK's current EPS growth estimate for next year is 44.5%, reflecting analyst expectations for robust financial performance.
Is AGBK a buy after the rally?
The upward EPS revision and 10.4% gain suggest positive momentum, but investors should monitor financial sector trends and interest rate movements for sustainability.
Why did WQEY stock jump in October 2026?
WQEY jumped 10.2% (from $8.61 to $9.49) after its EPS growth estimate for next year was revised from 34.0% to 46.3% on October 9.
The 12.4-percentage-point increase, detected by our screener, points to improving earnings prospects for the technology company. With no news catalyst, the rally likely reflects sector rotation into tech names with strong fundamentals. The revision suggests analysts are growing more confident in WQEY's ability to deliver above-average growth.
WQEY EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: WQEY
Why did WQEY stock surge?
WQEY surged 10.2% after its next-year EPS growth estimate was raised from 34.0% to 46.3% on October 9, indicating stronger earnings expectations.
Is WQEY a buy after the rally?
The upward revision supports a positive outlook, but the 10.2% jump may limit near-term upside; consider tech sector volatility and valuation.
What caused WQEY's EPS revision?
No specific news was found, but the revision likely reflects analyst upgrades to revenue and margin forecasts for the technology company.
Why did VRA stock jump in October 2026?
VRA jumped 9.5% (from $5.14 to $5.63) after its EPS growth estimate for next year was revised from 86.4% to 150.0% on October 9.
The massive 63.6-percentage-point upgrade, flagged by our screener, signals a dramatic improvement in expected profitability for the consumer cyclical company. With no company-specific news, the move may reflect broader optimism in retail stocks or a turnaround narrative. The magnitude of the revision suggests analysts see significant earnings acceleration ahead.
VRA EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: VRA
Why did VRA stock jump?
VRA jumped 9.5% after its forward EPS growth estimate was raised from 86.4% to 150.0% on October 9, indicating a sharp increase in expected earnings.
What is VRA's EPS growth estimate?
VRA's current EPS growth estimate for next year is 150.0%, up from 86.4%, reflecting analyst expectations for a major earnings rebound.
Is VRA a buy after the rally?
The extreme EPS revision suggests strong potential, but the 9.5% gain may already reflect much of the optimism; monitor consumer spending trends for confirmation.
Today's top performers highlight the market's reward for companies with upward EPS revisions, particularly in healthcare and technology. The strong gains in MRNA and NVAX suggest sector momentum, while AGBK, WQEY, and VRA show that earnings optimism is broad-based.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →